Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.78-0.20 (-1.43%)
At close: 04:00PM EST
13.75 -0.03 (-0.22%)
After hours: 07:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous close13.98
Open13.63
Bid13.75 x 900
Ask13.95 x 4000
Day's range13.35 - 14.00
52-week range8.37 - 18.48
Volume4,470,623
Avg. volume3,675,372
Market cap2.48B
Beta (5Y monthly)2.48
PE ratio (TTM)N/A
EPS (TTM)-1.27
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.33
  • Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week

    Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were skyrocketing 40.2% higher this week as of the market close on Thursday, according to on data from S&P Global Market Intelligence. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX990, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH).

  • Zacks

    BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

    BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

  • Zacks

    BioCryst (BCRX) Moves 27.9% Higher: Will This Strength Last?

    BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.